NEC Baby Formula Litigation (Premature Infant Injuries)

Necrotizing enterocolitis (NEC) is one of the most devastating diseases in neonatal medicine. It occurs when bacteria invade the wall of the intestine, causing inflammation, tissue death, and in severe cases, intestinal perforation. NEC primarily affects premature and very low birth weight infants (especially those born before 32 weeks gestational age or weighing less than 1,500 grams), with a mortality rate of 20–50% in the most severe cases. Survivors often face lifelong complications including short bowel syndrome (requiring long-term parenteral nutrition), feeding difficulties, growth failure, and neurodevelopmental delays.

The NEC baby formula litigation centers on a critical question: whether manufacturers of cow's-milk-based infant formula products — primarily Abbott Laboratories (Similac) and Mead Johnson Nutrition (Enfamil) — knew that their products significantly increased the risk of NEC in premature infants compared to human breast milk, yet aggressively marketed the products to neonatal intensive care units (NICUs) without adequate warnings.

The scientific evidence supporting the link between cow's-milk formula and NEC in premature infants is not new. Peer-reviewed research dating back to the 1990s has consistently demonstrated that premature infants fed cow's-milk-based formula develop NEC at rates 6 to 10 times higher than those fed exclusively with human breast milk. Major medical organizations — including the American Academy of Pediatrics (AAP) and the World Health Organization (WHO) — have recommended human breast milk as the preferred nutrition for premature infants specifically because of the NEC risk.

Despite this established science, plaintiffs allege that Abbott and Mead Johnson continued to market their formula products to NICUs without warning labels about the elevated NEC risk, and that their marketing practices actively undermined breastfeeding and donor human milk alternatives in hospital settings. Internal documents produced in discovery allegedly show that the companies were aware of the NEC risk but prioritized market share over patient safety.

The scientific evidence linking cow's-milk formula to NEC in premature infants is robust, has been established for decades, and is reflected in major medical organization guidelines.

A systematic review and meta-analysis published in Pediatrics found that formula-fed premature infants had approximately 6-10 times the risk of developing NEC compared to those fed exclusively human breast milk. The mechanism is well understood: human breast milk contains immunoglobulins (IgA), lactoferrin, human milk oligosaccharides, and other bioactive factors that protect the immature gut barrier, while cow's-milk proteins trigger inflammatory responses in the underdeveloped intestinal lining of premature infants.

The American Academy of Pediatrics has stated: 'Human milk is the preferred feeding for all infants, including premature and sick newborns, with rare exceptions.' The WHO similarly recommends exclusive breastfeeding, with pasteurized donor human milk as the second choice when mother's own milk is unavailable — with formula as a last resort for premature infants.

Despite these recommendations, formula manufacturers continued to market their products to NICUs and hospitals. Plaintiffs allege that marketing materials downplayed or omitted the NEC risk and that sales representatives actively competed to displace breast milk feeding programs.

Defendants have contested causation, arguing that NEC is multifactorial and that the science does not definitively prove their specific formula products caused NEC in individual infants. Courts have been divided on Daubert challenges to plaintiffs' expert testimony, with some judges excluding certain experts and others allowing the testimony to proceed.

Eligible families may include parents and guardians of premature infants (typically born before 37 weeks gestational age, and particularly those born before 32 weeks) who were fed cow's-milk-based infant formula — particularly Similac or Enfamil brand products — in the NICU and subsequently developed necrotizing enterocolitis. Cases involving infant death, bowel perforation, bowel resection surgery, short bowel syndrome, or long-term disability are particularly significant.

This eligibility information is general and informational only. Whether you have a viable legal claim depends on the specific facts of your situation and the laws of your jurisdiction. Consult a licensed attorney.

The MDL is active in the Northern District of Illinois before Judge Rebecca R. Pallmeyer. The litigation has produced mixed bellwether results:

The first bellwether trial — against Mead Johnson (Enfamil) — resulted in a landmark $60 million verdict for the plaintiff family in March 2024, significantly increasing settlement pressure.

However, on October 24, 2025, Judge Pallmeyer granted Abbott Laboratories' motion for summary judgment in the third bellwether case, finding insufficient evidence to proceed to trial in that specific case. This ruling was a significant defense victory and illustrates the complexity of establishing causation in individual NEC cases.

Defendants have faced mixed results on Daubert challenges to expert testimony. Some courts have excluded plaintiffs' causation experts, while others have found the scientific evidence sufficient to proceed. The litigation remains active with additional bellwether trials in preparation.

No global settlement has been reached. Both Abbott and Mead Johnson face substantial ongoing litigation exposure, though the mixed bellwether results complicate settlement dynamics.

Abbott Laboratories and Mead Johnson Nutrition have each argued that their products meet FDA nutritional requirements and are safe for their intended use. The defendants contend that NEC is a multifactorial disease with multiple contributing causes including prematurity itself, bacterial infection, gut immaturity, and various clinical factors — and that plaintiffs cannot establish that their formula products, rather than these other factors, caused NEC in individual infants.

Defendants have pointed out that for many premature infants, mother's own breast milk is not available in sufficient quantities, and that formula provides essential nutrition when breast milk alternatives are not feasible. They argue that their products have been used safely for millions of infants and that the NEC risk is associated with prematurity rather than formula feeding specifically.

Abbott and Mead Johnson have also challenged the admissibility of plaintiffs' expert testimony through Daubert motions, with varying success across different courts.

The first bellwether trial (March 2024) produced a $60 million verdict against Mead Johnson — a significant result that established the litigation's potential value. No global settlement has been announced, but the verdict has significantly increased pressure on both Abbott and Mead Johnson to negotiate resolution.

Individual case values are expected to vary based on the severity of the infant's condition and outcome, with fatal cases and cases involving severe long-term disability commanding the highest values.

Past settlement amounts are not a guarantee of future results. Individual claim values vary significantly.